A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye.


PURPOSE To investigate the efficacy and safety of an investigational integrin antagonist (SAR 1118) ophthalmic solution compared to placebo (vehicle) in subjects with dry eye disease. DESIGN Multicenter, prospective, double-masked, placebo-controlled trial. METHODS A total of 230 dry eye subjects selected with use of a controlled adverse environment… (More)
DOI: 10.1016/j.ajo.2011.11.003

7 Figures and Tables


  • Presentations referencing similar topics